- Prev close
- $70.31
- Day range
- $69.67 – $71.92
- Next earnings
- in 79 days
GE HealthCare’s flat session fits a quiet market tape, but the bigger driver is the July 23 prelim report that beat Q2 expectations, reaffirmed 2026 outlook, and came with a CFO transition; the setup is constructive but still needs execution proof given negative EPS growth and a PEG that is not meaningful.
GEHC
GE HEALTHCARE TECHNOLOGY
As of Aug 5, 2026
68/100
Worth keeping an eye onHealth ScoreWhy it moved
GEHC was essentially unchanged at -0.0% while the S&P 500 fell -0.2% and the Nasdaq 100 fell -0.9%, so the move was not driven by the broad market. With no peer move data provided, the clearest explanation is stock-specific digestion of the July 23 prelim Q2 update that beat expectations and included a CFO transition; the flat close suggests the news was largely absorbed rather than repriced in a one-session gap.
Normal volatility?
This looks like ordinary volatility rather than a deterioration signal. Revenue is still growing at +6.5% YoY (TTM) and the latest quarter was +5.8% YoY, while margins remain solid at gross +39.5%, operating +12.9%, and net +9.3%. The counterweight is EPS -11.0% YoY (TTM) and a PE of 16.0 with forward PE 13.5; the PEG is 2.30 but is not meaningful here because earnings growth is negative, so the multiple does not give a clean growth-adjusted read. Beta 0.82 also points to a stock that is typically less volatile than the market.
Earnings preview
The facts do not provide the next earnings date this period. What the market already has is the July 23 preliminary Q2 2026 release, which said GE HealthCare beat Q2 expectations, anticipated about 5.7% revenue growth for Q2, and reaffirmed the FY26 outlook. The main items still in focus are whether the company can sustain low-to-mid single-digit revenue growth, whether cost pressure from inflation and tariffs keeps operating margin at +12.9% from expanding, and how the CFO transition from Jay Saccaro to interim CFO George Newcomb affects guidance confidence.
This report is for informational and educational purposes only. It does not constitute financial, investment, tax, or legal advice. The platform does not recommend buying or selling any security.
Track GEHC with WhyIHold
Get a plain-English explanation the next time GE HEALTHCARE TECHNOLOGY makes a big move — so you know whether it's benign or worth your attention.